[1]
|
S. Pollard, B. Nashan, A. Johnston, P. Hoyer, P. Belitsky, P. Keown and H. Helderman, “A Pharmacokinetic and Clinical Review of the Potential Clinical Impact of Using Different Formulations of Cyclosporine A,” Clinical Therapeutics, Vol. 25, No. 6, 2003, pp. 1654-1669.
doi:10.1016/S0149-2918(03)80161-3
|
[2]
|
W. Carnahan and T. Y. Cooper, “Neoral to Gengraf Conversion in Renal Transplant Recipients,” Transplantation Proceedings, Vol. 35, No. 4, 2003, pp. 1308-1313.
doi:10.1016/S0041-1345(03)00423-8
|
[3]
|
J. S. Al Wakeel, F. A. Shaheen, M. C. Mathew, H. M. Abouzeinab, A. Al Afi, N. M. Tarif, M. S. Mousawi, T. S. Mahmoud, A. S. Alorrayad, E. A. Fagir, R. S. Dham and D. S. Shaker, “Six-month Clinical Outcome of Cyclosporine Microemulsion Formulation (Sigmasporin Microral) in Stable Renal Transplant Patients Previously Maintained on Sandimmun Neoral,” Transplantation Proceedings, Vol. 40, No. 7, 2008, pp. 2245-2251.
doi:10.1016/j.transproceed.2008.06.044
|
[4]
|
H. Müller, S. Solari, C. Zu?iga, C. Pedreros, J. Troncoso, C. Morente, R. Ovalle, P. Acosta, T. Chavez and E. Albornoz, “Immunosuppression with Generic Tacrolimus and Mycophenolate Mofetil in Renal Transplant Recipients: Preliminary Report in Chile,” Transplantation Proceedings, Vol. 40, No. 3, 2008, pp. 705-707.
doi:10.1016/j.transproceed.2008.02.056
|
[5]
|
“Public Assessment Report of the Medicines Evaluation Board in the Netherlands,”
http://db.cbg-meb.n/mri/par/nih-1340-001-002-003.pdf.
|
[6]
|
T. R. Türk, O. Witzke and M. Zeier, “KDIGO-Leitlinien Zur Betreuung von Nierentransplantatempf?ngern,” Nephrologe, Vol 5, No. 2, 2010, pp. 94-107.
doi:10.1007/s11560-009-0369-6
|
[7]
|
Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group, “KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients,” American Journal of Transplantation, Vol. 9, Suppl. 3, 2009, pp. S1-S155. doi:10.1111/j.1600-6143.2009.02834.x
|
[8]
|
J. D. Momper, T. A. Ridenour, K. S. Schonder, R. Shapiro, A. Humar and R. Venkatarmanan, “The Impact of Conversion from Prograf to Generic Tacrolimus in Liver and Kidney Transplant Recipients with Stable Graft Function,” American Journal of Transplantation, Vol. 11, No. 9, 2011, pp. 1861-1867.
doi:10.1111/j.1600-6143.2011.03615.x
|
[9]
|
G. B. Klintmalm, “Immunosuppression, Generic Drugs and the FDA,” American Journal of Transplantation, Vol. 11, No. 9, 2011, pp. 1765-1766.
doi:10.1111/j.1600-6143.2011.03616.x
|
[10]
|
J. H. Helderman, N. Kang, A. P. Legoretta and J. Y. Chen, “Healthcare Costs in Renal Transplant Recipients Using Branded versus Generic Cyclosporine,” Applied Health Economics and Health Policy, Vol. 8, No. 1, 2010, pp. 61-68.
|
[11]
|
L. M. McDevitt-Potter, B. Sadaka, E. M. Tichy, C. C. Rogers and S. Gabardi, “A multicenter Experience with Generic Tacrolimus Conversion,” Transplantation, Vol. 92, No. 6, 2011, pp. 653-657.
doi:10.1097/TP.0b013e31822a79ad
|
[12]
|
E. G. Hagenmeyer, B. H?ussler, E. Hempel, G. Grannas, Z. Kaló, A. Kilburg and B. Nashan, “Resource Use and Treatment Costs after Kidney Tranplantation: Impact of Demographic Factors, Comorbidities, and Complications,” Transplantation, Vol. 77, No. 1, 2004, pp. 1545-1550.
|